# RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

> **NCT06063018** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Cervical Cancer Recurrent

## Interventions

- **DRUG:** RC48 + Tislelizumab

## Key facts

- **NCT ID:** NCT06063018
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-16
- **Primary completion:** 2025-08
- **Final completion:** 2026-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06063018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06063018, "RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06063018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*